ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers

Clinical and Experimental Immunology

Volumn 163, Issue 3, 2011, Pages 324-332

  Sinnathamby, G ^a   Zerfass, J ^a   Hafner, J ^a   Block, P ^a   Nickens, Z ^a   Hobeika, A ^b   Secord, A A ^b   Lyerly, H K ^b   Morse, M A ^b   Philip, R ^a  

^a Immunotope Inc   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

CTL; Immunotherapy; MHC class I; T cell epitope; Tumour antigen

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; EPITOPE; GAMMA INTERFERON; GRANZYME B; HLA A2 ANTIGEN; HLA ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADAM PROTEINS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE PROTEINS; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79551700835     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04298.x     Document Type: Article

References (31)

1. Shastri N, Schwab S, Serwold T. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu Rev Immunol 2002; 20:463-93.
2. Admon A, Barnea E, Ziv T. Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol Cell Proteomics 2003; 2:388-98.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
4. Ramakrishna V, Ross MM, Petersson M etal. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 2003; 15:751-63.
5. Sinnathamby G, Lauer P, Zerfass J etal. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. J Immunother 2009; 32:856-69.
6. Karkada M, Weir GM, Quinton T etal. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. J Immunother 2010; 33:250-61.
7. Black RA, Rauch CT, Kozlosky CJ etal. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385:729-33.
8. Moss ML, Jin SL, Milla ME etal. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385:733-6.
9. Lee DC, Sunnarborg SW, Hinkle CL etal. TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann NY Acad Sci 2003; 995:22-38.
10. Le Gall SM, Bobe P, Reiss K etal. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. Mol Biol Cell 2009; 20:1785-94.
11. Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007; 117:337-45.
12. Merchant NB, Voskresensky I, Rogers CM etal. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 2008; 14:1182-91.
13. Rosso O, Piazza T, Bongarzone I etal. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res 2007; 5:1246-53.
14. Ongusaha PP, Kwak JC, Zwible AJ etal. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 2004; 64:5283-90.
15. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 2003; 22:1114-24.
16. Berasain C, Castillo J, Perugorria MJ, Prieto J, Avila MA. Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett 2007; 254:30-41.
17. van der Bruggen P, Traversari C, Chomez P etal. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-7.
18. Goldman B. Cancer vaccines: finding the best way to train the immune system. J Natl Cancer Inst 2002; 94:1523-6.
19. Lewis JD, Reilly BD, Bright RK. Tumor-associated antigens: from discovery to immunity. Int Rev Immunol 2003; 22:81-112.
20. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004; 4:401-11.
21. Gschwind A, Hart S, Fischer OM, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 2003; 22:2411-21.
22. Peiretti F, Deprez-Beauclair P, Bonardo B, Aubert H, Juhan-Vague I, Nalbone G. Identification of SAP97 as an intracellular binding partner of TACE. J Cell Sci 2003; 116:1949-57.
23. Nelson KK, Schlondorff J, Blobel CP. Evidence for an interaction of the metalloprotease-disintegrin tumour necrosis factor alpha convertase (TACE) with mitotic arrest deficient 2 (MAD2), and of the metalloprotease-disintegrin MDC9 with a novel MAD2-related protein, MAD2beta. Biochem J 1999; 343:673-80.
24. Martelange V, De Smet C, De Plaen E, Lurquin C, Boon T. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res 2000; 60:3848-55.
25. Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 2001; 22:516-23.
26. Mathieu MG, Linley AJ, Reeder SP etal. HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers. Cancer Immun 2010; 10:2.
27. Chen G, Gharib TG, Huang CC etal. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 1:304-13.
28. Rogel A, Popliker M, Webb CG, Oren M. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 1985; 5:2851-5.
29. Chiriva-Internati M, Grizzi F, Bright RK, Martin Kast W. Cancer immunotherapy: avoiding the road to perdition. J Transl Med 2004; 2:26.
30. Vierboom MP, Zwaveling S, Bos GMJ etal. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res 2000; 60:5508-13.
31. Horiuchi K, Le Gall S, Schulte M etal. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 2007; 18:176-88.